Autonomix Medical Closes $10M Public Offering with Warrants to Fund Clinical Trials | AMIX Stock News
Summary
The securities comprising the units were immediately separable and were issued separately.Ladenburg Thalmann & Co. Inc. acted as the sole bookrunning manager for the offering.The Company intends to use the net proceeds from this offering to fund its clinical trial, for other research and development, for development of intellectual property, and for working capital.The securities described above were offered by the Company pursuant to a registration statement on Form S-1 (No. Electronic copies of the final prospectus may be obtained from Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New York, New York 10019, or by telephone at (212) 409-2000, or by email at prospectus@ladenburg.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading Risk Factors and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024, and from time to time, our other filings with the SEC.